A Pilot Study Comparing the Safety and Efficacy of Zortress (Everolimus) With Low Dose Tacrolimus to Early Conversion to Calcineulin Inhibitor-Free Regimen and Mycophenolic Acid With Standard Dose Tacrolimus in Recipients of ECD/DCD Kidneys

Trial Profile

A Pilot Study Comparing the Safety and Efficacy of Zortress (Everolimus) With Low Dose Tacrolimus to Early Conversion to Calcineulin Inhibitor-Free Regimen and Mycophenolic Acid With Standard Dose Tacrolimus in Recipients of ECD/DCD Kidneys

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 02 May 2017

At a glance

  • Drugs Everolimus (Primary) ; Tacrolimus (Primary) ; Corticosteroids; Mycophenolate mofetil
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Acronyms Evered
  • Most Recent Events

    • 26 Apr 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Nov 2017.
    • 13 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Mar 2017.
    • 22 Jul 2015 Planned End Date changed from 1 Jun 2015 to 1 Dec 2017 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top